Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Convergence Pharmaceuticals has commenced a randomised, placebo controlled Phase I study to evaluate the safety and tolerability of single ascending orally administered doses of CNV2197944 to treat chronic pain.
Subscribe to our email newsletter
CNV2197944 is a small molecule, state-dependent calcium channel blocker, intended to selectively inhibit highly active Cav2.2 channels.
In preclinical studies, CNV2197944 has demonstrated safety and efficacy profile.
Convergence Pharma expects to complete the Phase I study of the calcium channel blocker CNV2197944 in the Q3 of 2011.
Convergence Pharma CEO Simon Tate said they believe the mode of action of CNV2197944 has the potential to increase the efficacy whilst minimising the unwanted side effects of current pain treatments and will have a significant effect on the quality of life of chronic pain sufferers.